PMID- 15181049
OWN - NLM
STAT- MEDLINE
DCOM- 20040719
LR  - 20181130
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 89
IP  - 6
DP  - 2004 Jun
TI  - Evidence for a potent antiinflammatory effect of rosiglitazone.
PG  - 2728-35
AB  - We have recently demonstrated a potent antiinflammatory effect of troglitazone, 
      an agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) and a 
      partial agonist of PPARalpha in both the nondiabetic obese and diabetic obese 
      subjects. We have now investigated the antiinflammatory actions of rosiglitazone, 
      a selective PPARgamma agonist. Eleven nondiabetic obese subjects and 11 obese 
      diabetic subjects were each given 4 mg of rosiglitazone daily for a period of 6 
      wk. Fasting blood samples were obtained at 0, 1, 2, 4, 6, and 12 wk (6 wk after 
      the cessation of rosiglitazone). Eight obese subjects and five obese diabetic 
      subjects were also included in the study as control groups. Fasting blood samples 
      were obtained from the control groups at 0, 1, 2, 4, and 6 wk only. Nuclear 
      factor kappaB (NFkappaB)-binding activity in mononuclear cells, plasma monocyte 
      chemoattractant protein-1 (MCP-1), TNF-alpha, soluble intercellular adhesion 
      molecule-1, C-reactive protein (CRP), and serum amyloid A (SAA) were measured. 
      Blood glucose concentration changed significantly at 6 wk only in the obese 
      diabetic subjects after rosiglitazone treatment for 6 wk, whereas insulin 
      concentration decreased significantly at 6 wk in both groups. NFkappaB-binding 
      activity in mononuclear cell nuclear extract fell in both obese and obese 
      diabetic subjects (P < 0.02). Rosiglitazone treatment resulted in a reduction in 
      plasma MCP-1 and CRP in both groups (P < 0.05). Plasma TNF-alpha and SAA 
      concentrations were inhibited significantly in the obese group (P < 0.05) but not 
      in the obese diabetic subjects. NFkappaB-binding activity and plasma MCP-1, CRP, 
      SAA, and TNF-alpha did not change in the obese and obese diabetic control groups. 
      We conclude that rosiglitazone, a selective PPARgamma agonist, exerts an 
      antiinflammatory effect at the cellular and molecular level, and in plasma. These 
      observations may have implications for atherogenesis in the long term in subjects 
      treated with rosiglitazone and possibly other thiazolidinediones.
FAU - Mohanty, Priya
AU  - Mohanty P
AD  - Division of Endocrinology, Diabetes and Metabolism, State University of New York, 
      and Kaleida Health, Buffalo, New York 14209, USA.
FAU - Aljada, Ahmad
AU  - Aljada A
FAU - Ghanim, Husam
AU  - Ghanim H
FAU - Hofmeyer, Deborah
AU  - Hofmeyer D
FAU - Tripathy, Devjit
AU  - Tripathy D
FAU - Syed, Tufail
AU  - Syed T
FAU - Al-Haddad, Waddah
AU  - Al-Haddad W
FAU - Dhindsa, Sandeep
AU  - Dhindsa S
FAU - Dandona, Paresh
AU  - Dandona P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Insulin)
RN  - 0 (NF-kappa B)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Transcription Factor RelA)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Blood Glucose
MH  - C-Reactive Protein/metabolism
MH  - Chemokine CCL2/blood
MH  - Diabetes Mellitus/*drug therapy/immunology/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/immunology/metabolism
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - I-kappa B Proteins/metabolism
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Intercellular Adhesion Molecule-1/blood
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Middle Aged
MH  - NF-kappa B/metabolism
MH  - *Obesity
MH  - Rosiglitazone
MH  - Solubility
MH  - Thiazolidinediones/*administration & dosage
MH  - Transcription Factor RelA
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2004/06/08 05:00
MHDA- 2004/07/20 05:00
CRDT- 2004/06/08 05:00
PHST- 2004/06/08 05:00 [pubmed]
PHST- 2004/07/20 05:00 [medline]
PHST- 2004/06/08 05:00 [entrez]
AID - 89/6/2728 [pii]
AID - 10.1210/jc.2003-032103 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2004 Jun;89(6):2728-35. doi: 10.1210/jc.2003-032103.